Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Oct;8(10):E1260-E1267.
doi: 10.21037/jtd.2016.10.16.

Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?

Vaibhav R Vaidya  1 , Roshini Asirvatham  2 , Jason Tri  2 , Samuel J Asirvatham  3
Affiliations
Editorial

Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?

Vaibhav R Vaidya et al. J Thorac Dis. 2016 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Autopsy specimens from 136 consecutive nonrheumatic AF patients without anticoagulation compared with 231 age-matched controls without AF. Data from Yamanouchi et al. (13). AF, atrial fibrillation.
Figure 2
Figure 2
Comparison of ischemic and hemorrhagic stroke risk between Watchman trials and NOAC trials. *, events per 100 patient-years; , updated PREVAIL data from Waksman et al. (24), references for PROTECT AF [2009] (4), PROTECT AF [2014] (5), ARISTOTLE (25), ROCKET-AF (26), RE-LY (27); AF, atrial fibrillation; ICH, intracranial hemorrhage.
See this image and copyright information in PMC

Comment on

References

    1. Food and Drug Administration. Premarket approval application (PMA) for the WATCHMAN LAA Closure Technology. 2016. Available online: http://101.96.10.42/www.accessdata.fda.gov/cdrh_docs/pdf13/p130013a.pdf
    1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47. 10.1161/CIRCULATIONAHA.113.005119 - DOI - PMC - PubMed
    1. Holmes DR, Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12. 10.1016/j.jacc.2014.04.029 - DOI - PubMed
    1. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42. 10.1016/S0140-6736(09)61343-X - DOI - PubMed
    1. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9. 10.1161/CIRCULATIONAHA.112.114389 - DOI - PubMed

LinkOut - more resources